RxSight, Inc. (NASDAQ:RXST - Get Free Report) CFO Shelley B. Thunen sold 10,000 shares of the firm's stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $52.69, for a total transaction of $526,900.00. Following the completion of the transaction, the chief financial officer now directly owns 13,938 shares in the company, valued at $734,393.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
RxSight Price Performance
Shares of NASDAQ RXST opened at $59.63 on Friday. RxSight, Inc. has a 12-month low of $18.09 and a 12-month high of $59.70. The company's fifty day simple moving average is $52.51 and its 200 day simple moving average is $42.44.
RxSight (NASDAQ:RXST - Get Free Report) last announced its earnings results on Wednesday, February 28th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.10. The company had revenue of $28.58 million during the quarter, compared to the consensus estimate of $28.60 million. RxSight had a negative net margin of 54.57% and a negative return on equity of 31.16%. As a group, sell-side analysts forecast that RxSight, Inc. will post -0.94 EPS for the current fiscal year.
Institutional Trading of RxSight
Forget Bitcoin: This $8 Stock Is the Next Big Thing
From Behind the Markets | Ad
4x Better than Bitcoin
Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Get the name of the stock here >>>
Large investors have recently added to or reduced their stakes in the stock. FORA Capital LLC boosted its position in RxSight by 5.6% during the first quarter. FORA Capital LLC now owns 11,695 shares of the company's stock worth $603,000 after purchasing an additional 622 shares during the period. Capstone Investment Advisors LLC raised its position in shares of RxSight by 698.4% during the 1st quarter. Capstone Investment Advisors LLC now owns 127,200 shares of the company's stock valued at $6,561,000 after buying an additional 111,269 shares in the last quarter. Baillie Gifford & Co. purchased a new stake in RxSight in the first quarter worth approximately $3,429,000. Principal Financial Group Inc. boosted its position in RxSight by 298.5% during the first quarter. Principal Financial Group Inc. now owns 34,928 shares of the company's stock valued at $1,802,000 after buying an additional 26,164 shares during the period. Finally, Counterpoint Mutual Funds LLC increased its stake in RxSight by 102.9% in the 1st quarter. Counterpoint Mutual Funds LLC now owns 13,573 shares of the company's stock worth $700,000 after purchasing an additional 6,883 shares during the period. Hedge funds and other institutional investors own 78.78% of the company's stock.
Analyst Ratings Changes
A number of research firms have weighed in on RXST. Stifel Nicolaus boosted their target price on shares of RxSight from $54.00 to $64.00 and gave the stock a "buy" rating in a report on Thursday, February 29th. Oppenheimer boosted their target price on shares of RxSight from $54.00 to $61.00 and gave the stock an "outperform" rating in a report on Thursday, February 29th. Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 price objective on shares of RxSight in a research note on Thursday, April 11th. Finally, JPMorgan Chase & Co. upped their price objective on shares of RxSight from $40.00 to $62.00 and gave the company an "overweight" rating in a research note on Thursday, February 29th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $49.63.
Get Our Latest Report on RxSight
About RxSight
(
Get Free Report)
RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
